7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
https://doi.org/10.1016/j.jtho.2021.08.245
Copy DOIJournal: Journal of Thoracic Oncology | Publication Date: Oct 1, 2021 |
Citations: 2 | License type: publisher-specific-oa |
The detection of driver gene mutations, such as epidermal growth factor receptor (EGFR) mutations, plays a decisive role in the treatment of non-small cell lung cancer (NSCLC). Cobas EGFR mutation test is a mutant allele-specific real-time PCR assay that is commonly used in daily practice. It has a notable intrinsic detection limitation caused by its primer designs. Next-generation sequencing (NGS) is a comprehensive mutation assay that does not have the constraint. It will have a higher mutation detection rate but the clinical impact remains uncertain.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.